-
-
-
-
-
-
-
Exelixis (EXEL) PT Raised to $51 at Truist Securities
-
-
-
-
-
-
-
Exelixis' (EXEL) Zanzalintinib Centerpiece of Near-term Strategy - Stifel
-
-
-
-
-
-
-
Truist on Exelixis (EXEL): 'STELLAR-303 Unlikely To Drive Broad Adoption'
-
-
-
-
-
-
-
Exelixis (EXEL) PT Lowered to $45 at RBC Capital
-
-
-
-
-
-
-
Citizens JMP Reiterates Market Outperform Rating on Exelixis (EXEL)
-
-
-
-
-
-
-
Exelixis (EXEL) PT Raised to $55 at Truist Following 'A Nice First Pivotal Win'
-
-
-
-
-
-
-
Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

